OncLive® On Air

Non-Small Cell Lung Cancer

Breast Cancer

Immunotherapy

Clinical Trials

Multiple Myeloma

Small Cell Lung Cancer

Bladder Cancer

Prostate Cancer

Chemotherapy

Triple Negative Breast Cancer

Pembrolizumab

Chronic Lymphocytic Leukemia

Oncology

Antibody Drug Conjugates

Chronic Myeloid Leukemia

Hr-Positive Her2-Negative Metastatic Breast Cancer

PARP Inhibitors

Metastatic Breast Cancer

Surgery

Biomarker Testing

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers,... more

33 ratings

Publishes	Daily	Episodes	500	Founded	8 years ago
Number of Listeners		Categories	Health & FitnessScience

Listen to this Podcast

Guests Reviews Talking Points

Latest Episodes

S17 Ep75: Key Considerations for Health Equity and Patient-Centered Care in TNBC

Highlights from the PER® CME activity "Key Considerations for Health Equity and Patient-Centered Care in TNBC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In thi... more

17 Aug 2026 • 25 min

S17 Ep77: FDA Approval Insights: Gedatolisib Plus Fulvestrant ± Palbociclib for HR+, HER2-Negative, PIK3CA Wild-Type Advanced Breast Cancer: With Adam M. Brufsky, MD, PhD

In today’s episode, we spoke with Adam M. Brufsky, MD, PhD, about the FDA approval of gedatolisib (Revtorpyk) plus fulvestrant (Faslodex), with or without palbociclib (Ibrance), for the treatment of adult patients with hormone receptor–positive, HER2... more

14 Aug 2026 • 10 min

S17 Ep76: Greater Flexibility and Improved QOL Represent Key Potential Benefits With Liquid TKI Formulations: With Jonathan Trent, MD, PhD

In today’s episode, we spoke with Jonathan Trent, MD, PhD, a professor in the Department of Medicine in the Division of Medical Oncology, associate director of Clinical Research, and the director of the Sarcoma Medical Research Program at the Univers... more

7 Aug 2026 • 15 min • Popular

S17 Ep74: Precision Oncology, Bispecific Antibodies, and Next-Generation Targeted Therapies Are Reshaping NSCLC Care: With Chandler Park, MD; Stephen V. Liu, MD

In this episode of Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Stephen V. Liu, MD, the division chief of Hematology Oncology at MedStar Georgetown University Hospi... more

4 Aug 2026 • 23 min • Most popular

Key Facts

Accepts Guests

Contact Information

Podcast Host

Number of Listeners

Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Two Onc DocsSam and Karine

Oncology Brothers: Practice-Changing Cancer DiscussionsOncology Brothers

Oncology Today with Dr Neil LoveDr. Neil Love

Research To Practice | Oncology VideosDr Neil Love

ASCO Daily NewsAmerican Society of Clinical Oncology (ASCO)

Recent Guests

Jonathan Trent

MD, PhD, oncologist

Episode: S17 Ep76: Greater Flexibility and Improved QOL Represent Key Potential Benefits With Liquid TKI Formulations: With Jonathan Trent, MD, PhD

Dr. Stephen Liu

Division Chief of Hematology Oncology, MedStar Georgetown University

MedStar Georgetown University

Episode: S17 Ep74: Precision Oncology, Bispecific Antibodies, and Next-Generation Targeted Therapies Are Reshaping NSCLC Care: With Chandler Park, MD; Stephen V. Liu, MD

Douglas W. Sborov

MD, MS; oncologist

Episode: S17 Ep72: FDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov, MD, MS

Solange Peters

MD, PhD, full professor and chair of medical oncology and thoracic malignancies at the University Hospital of Lausanne, Switzerland

University Hospital of Lausanne

Episode: S17 Ep69: Positioning PD-L1/VEGF Bispecifics in First-Line Non–Small Cell Lung Cancer: With Solange Peters, MD, PhD

Tanios S. Bekaii-Saab, MD

Medical oncologist discussed as the interview guest

Episode: S17 Ep71: Biomarker-Driven Shifts Signal the Next Generation of mCRC Therapies: With Tanios S. Bekaii-Saab, MD

John N. Allan, MD

MD discussed in exclusive interview

Episode: S17 Ep70: Navigating Fixed-Durations Regimens in CLL and Improving Outcomes for High-Risk Patients: With John N. Allan, MD

Marlana M. Orloff, MD

Alexander and Johnson family endowed clinical director in uveal melanoma; Associate Professor at Thomas Jefferson University Hospital

Thomas Jefferson University Hospital

Episode: S17 Ep68: Sequencing Systemic and Liver-Directed Therapy in HLA-A*02:01–Negative Metastatic Uveal Melanoma: With Marlana M. Orloff, MD

Everett Meyer

MD, PhD, transplant oncologist discussing Orca-T approval and trial data

[not specified]

Episode: S17 Ep66: FDA Approval Insights: Orca-T Raises the Bar for Allogeneic Transplants in Hematologic Malignancies: With Everett Meyer, MD, PhD

Paolo Tarantino

MD, PhD; expert in oncology discussing ASCO 2026 breast cancer ADC data

Episode: S17 Ep65: ASCO 2026 ADC Data Clarify Some Strategies and Raise Further Questions for Breast Cancer Care: With Paolo Tarantino, MD, PhD

Reviews

4.5 out of 5 stars from 33 ratings

Best option for CME podcasts
Love the content! Easily the best platform for listening to CME and staying updated while on the go. Keep up the great work!
Apple Podcasts
5
Dlshaka
United Statesa year ago
My favorite podcast for oncology
This podcast provides excellent information to anyone who works in the medical field on oncology.
Apple Podcasts
5
Chiliman1986
United States7 years ago

Embed These Reviews on a Website

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

Listeners value data-driven discussion and expert guest diversity.

Great CME content for clinicians and researchers.

High-quality oncology insights and practical takeaways.

Top Health & Fitness Podcasts

The Dylan Gemelli PodcastDylan Gemelli

On Purpose with Jay ShettyPerfect Strangers

Passion Struck with John R. MilesPassion Struck with John R. Miles

We're Out of TimeRichard Taite

Tony Mantor: Why Not Me ?iHeartPodcasts

Huberman LabScicomm Media

The Dr. John Delony ShowRamsey Network

Nothing much happens: bedtime stories to help you sleepWellness Loud

The Dr. Josh Axe ShowDr. Josh Axe

Get Sleepy: Sleep meditation and storiesSlumber Studios

Talking Points

Recent interactions between the hosts and their guests.

S17 Ep70: Navigating Fixed-Durations Regimens in CLL and Improving Outcomes for High-Risk Patients: With John N. Allan, MD

Q: In your review, what is one short take-home message for colleagues about this work?

Reviews synthesize a broad and rapidly evolving evidence base, providing a consolidated, up-to-date reference that helps clinicians quickly locate data, apply current best practices, and anticipate future directions, including the role of MRD guidance and fixed-duration strategies in everyday patient care.

S17 Ep70: Navigating Fixed-Durations Regimens in CLL and Improving Outcomes for High-Risk Patients: With John N. Allan, MD

Q: Following the review, what are the biggest remaining unmet needs in CLL regarding fixed-duration regimens?

Key unmet needs include optimizing treatment for high-risk patients such as those with 17p deletions or complex karyotypes, understanding long-term outcomes and resistance patterns, and integrating MRD-guided strategies to tailor duration and intensity of therapy, as well as exploring new molecules and combinations to address resistance mechanisms.

S17 Ep70: Navigating Fixed-Durations Regimens in CLL and Improving Outcomes for High-Risk Patients: With John N. Allan, MD

Q: In your review, what was the most striking finding regarding safety among fixed-duration regimens in CLL?

Second-generation BTK inhibitor–venetoclax combinations showed favorable cardiovascular safety, with very low atrial fibrillation and cardiovascular event rates in frontline studies, while cytopenias and infections were generally higher with triplet regimens but manageable with careful monitoring, indicating a favorable safety landscape for fixed-duration regimens overall.

S17 Ep70: Navigating Fixed-Durations Regimens in CLL and Improving Outcomes for High-Risk Patients: With John N. Allan, MD

Q: Why are fixed-duration regimens so important?

Fixed-duration regimens offer a balance between effective disease control and reduced long-term exposure to drugs, potentially lowering cumulative toxicity. They provide a defined treatment window, allow patients to be off therapy earlier, and can simplify management while maintaining comparable efficacy in many patients, especially with newer combinations showing favorable safety signals.

S17 Ep70: Navigating Fixed-Durations Regimens in CLL and Improving Outcomes for High-Risk Patients: With John N. Allan, MD

Q: Can you give us background on what the treatment landscape looks like for CLL right now? How does this current landscape compare to the past?

The landscape has shifted toward fixed-duration oral regimens, particularly BTK inhibitors plus venetoclax, and new fixed-duration approaches including calabrutinib-venetoclax. While continuous therapies remain an option, fixed-duration regimens are increasingly practical, with efforts to personalize therapy based on patient risk and response, and ongoing comparisons to older regimens indicate similar efficacy with potentially better safety and stop-ability for many patients.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About OncLive® On Air

What is OncLive® On Air about and what kind of topics does it cover?

A biomedical-focused interview series features in-depth conversations with academic oncologists and physician-recholers who dissect cutting-edge oncology data, trials, and therapeutic strategies. Topics span targeted therapies, antibody-drug conjugates, immunotherapy combinations, precision oncology, and novel delivery methods across solid tumors and hematologic malignancies. Episodes emphasize practical takeaways for clinical practice, real-world constraints, biomarker-driven decision-making, and the evolving treatment landscape presented at major conferences. A standout pattern is how guests translate complex trial results into actionable insights for clinicians, with recurring attention to safety signals, sequencing, patient quality of l... more

Where can I find podcast stats for OncLive® On Air?

Rephonic provides a wide range of podcast stats for OncLive® On Air. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to OncLive® On Air and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does OncLive® On Air get?

Rephonic provides a full set of podcast information for four million podcasts, including the number of listeners. View further listenership figures for OncLive® On Air, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for OncLive® On Air?

Rephonic provides comprehensive predictive audience data for OncLive® On Air, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does OncLive® On Air have?

To see how many followers or subscribers OncLive® On Air has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to OncLive® On Air?

These podcasts share a similar audience with OncLive® On Air:

1. Two Onc Docs
2. Oncology Brothers: Practice-Changing Cancer Discussions
3. Oncology Today with Dr Neil Love
4. Research To Practice | Oncology Videos
5. ASCO Daily News

How many episodes of OncLive® On Air are there?

OncLive® On Air launched 8 years ago and published 500 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact OncLive® On Air?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for OncLive® On Air?

Rephonic pulls ratings and reviews for OncLive® On Air from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for OncLive® On Air?

Rephonic provides full transcripts for episodes of OncLive® On Air. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on OncLive® On Air?

Recent guests on OncLive® On Air include:

1. Jonathan Trent
2. Dr. Stephen Liu
3. Douglas W. Sborov
4. Solange Peters
5. Tanios S. Bekaii-Saab, MD
6. John N. Allan, MD
7. Marlana M. Orloff, MD
8. Everett Meyer

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.

Try it free for 7 days